These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 35964548)

  • 1. Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer.
    Rugo HS; Bianchini G; Cortes J; Henning JW; Untch M
    ESMO Open; 2022 Aug; 7(4):100553. PubMed ID: 35964548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Practices and Institutional Protocols on Prophylaxis, Monitoring, and Management of Selected Adverse Events Associated with Trastuzumab Deruxtecan.
    Bardia A; Harnden K; Mauro L; Pennisi A; Armitage M; Soliman H
    Oncologist; 2022 Aug; 27(8):637-645. PubMed ID: 35642907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trastuzumab deruxtecan in previously treated HER2-positive metastatic breast cancer: Plain language summary of the DESTINY-Breast01 study.
    Modi S
    Future Oncol; 2021 Sep; 17(26):3415-3423. PubMed ID: 34263665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel.
    Chiu JWY; Lee SC; Ho JC; Park YH; Chao TC; Kim SB; Lim E; Lin CH; Loi S; Low SY; Teo LLS; Yeo W; Dent R
    Drug Saf; 2023 Oct; 46(10):927-949. PubMed ID: 37552439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Perspectives and Practices for Pneumonitis/Interstitial Lung Disease Associated With Trastuzumab Deruxtecan Use in Human Epidermal Growth Factor Receptor 2-Expressing Metastatic Breast Cancer.
    Rugo HS; Crossno CL; Gesthalter YB; Kelley K; Moore HB; Rimawi MF; Westbrook KE; Buys SS
    JCO Oncol Pract; 2023 Aug; 19(8):539-546. PubMed ID: 37207306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exposure-Response Relationships in Patients With HER2-Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab Deruxtecan.
    Yin O; Iwata H; Lin CC; Tamura K; Watanabe J; Wada R; Kastrissios H; AbuTarif M; Garimella T; Lee C; Zhang L; Shahidi J; LaCreta F
    Clin Pharmacol Ther; 2021 Oct; 110(4):986-996. PubMed ID: 33999422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer.
    Narayan P; Osgood CL; Singh H; Chiu HJ; Ricks TK; Chiu Yuen Chow E; Qiu J; Song P; Yu J; Namuswe F; Guiterrez-Lugo M; Hou S; Pierce WF; Goldberg KB; Tang S; Amiri-Kordestani L; Theoret MR; Pazdur R; Beaver JA
    Clin Cancer Res; 2021 Aug; 27(16):4478-4485. PubMed ID: 33753456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study.
    Botticelli A; Caputo R; Scagnoli S; Pisegna S; De Laurentiis M; Curigliano G; Lambertini M; Pantano F; Palazzo A; Paris I; Vernieri C; Tedesco B; Giampaglia M; Palleschi M; Ballatore Z; Alesini D; D'Auria G; Fabbri A; Rossi L; Verrazzo A; Scafetta R; Marinelli D; Sposetti C; Barberi V; Strigari L; Marchetti P; Santini D; Fabi A
    Oncologist; 2024 Apr; 29(4):303-310. PubMed ID: 37995313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Chinese expert consensus on the management of clinical pathway and adverse events of trastuzumab deruxtecan (2024 edition)].
    Trastuzumab Deruxtecan Clinical Management Pathway and Adverse Reaction Management Consensus Expert Group
    Zhonghua Zhong Liu Za Zhi; 2024 Apr; 46(4):304-318. PubMed ID: 38644266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Review of Fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Breast Cancer.
    Nguyen X; Hooper M; Borlagdan JP; Palumbo A
    Ann Pharmacother; 2021 Nov; 55(11):1410-1418. PubMed ID: 33629601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety profile of trastuzumab deruxtecan in advanced breast cancer: Expert opinion on adverse event management.
    Ciruelos E; García-Sáenz JÁ; Gavilá J; Martín M; Rodríguez CA; Rodríguez-Lescure Á
    Clin Transl Oncol; 2024 Jul; 26(7):1539-1548. PubMed ID: 38336982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of Adverse Events Associated with Trastuzumab Deruxtecan in Patients with Gastric and Breast Cancer: A Retrospective Study.
    Nonomiya Y; Nakayama I; Kobayashi K; Amakawa Y; Shibata N; Soejima A; Kawakami K; Shimizu H; Takahari D; Kawai S; Hara F; Takano T; Yamaguchi K; Yamaguchi M
    Biol Pharm Bull; 2024; 47(2):411-416. PubMed ID: 38346748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies.
    Powell CA; Modi S; Iwata H; Takahashi S; Smit EF; Siena S; Chang DY; Macpherson E; Qin A; Singh J; Taitt C; Shire N; Camidge DR
    ESMO Open; 2022 Aug; 7(4):100554. PubMed ID: 35963179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial.
    Smit EF; Felip E; Uprety D; Nagasaka M; Nakagawa K; Paz-Ares Rodríguez L; Pacheco JM; Li BT; Planchard D; Baik C; Goto Y; Murakami H; Saltos A; Pereira K; Taguchi A; Cheng Y; Yan Q; Feng W; Tsuchihashi Z; Jänne PA
    Lancet Oncol; 2024 Apr; 25(4):439-454. PubMed ID: 38547891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study.
    Curigliano G; Dunton K; Rosenlund M; Janek M; Cathcart J; Liu Y; Fasching PA; Iwata H
    Ann Oncol; 2023 Jul; 34(7):569-577. PubMed ID: 37179020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trastuzumab deruxtecan for HER2+ advanced breast cancer.
    Lee J; Park YH
    Future Oncol; 2022 Jan; 18(1):7-19. PubMed ID: 34823373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial.
    André F; Hee Park Y; Kim SB; Takano T; Im SA; Borges G; Lima JP; Aksoy S; Gavila Gregori J; De Laurentiis M; Bianchini G; Roylance R; Miyoshi Y; Armstrong A; Sinha R; Ruiz Borrego M; Lim E; Ettl J; Yerushalmi R; Zagouri F; Duhoux FP; Fehm T; Gambhire D; Cathcart J; Wu C; Chu C; Egorov A; Krop I
    Lancet; 2023 May; 401(10390):1773-1785. PubMed ID: 37086745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.
    Modi S; Saura C; Yamashita T; Park YH; Kim SB; Tamura K; Andre F; Iwata H; Ito Y; Tsurutani J; Sohn J; Denduluri N; Perrin C; Aogi K; Tokunaga E; Im SA; Lee KS; Hurvitz SA; Cortes J; Lee C; Chen S; Zhang L; Shahidi J; Yver A; Krop I;
    N Engl J Med; 2020 Feb; 382(7):610-621. PubMed ID: 31825192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01).
    Saura C; Modi S; Krop I; Park YH; Kim SB; Tamura K; Iwata H; Tsurutani J; Sohn J; Mathias E; Liu Y; Cathcart J; Singh J; Yamashita T
    Ann Oncol; 2024 Mar; 35(3):302-307. PubMed ID: 38092229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer.
    Shitara K; Baba E; Fujitani K; Oki E; Fujii S; Yamaguchi K
    Gastric Cancer; 2021 Jul; 24(4):780-789. PubMed ID: 33997928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.